CPT® Code 80350

Official Description

Cannabinoids, synthetic; 1-3

Common Language Description

The CPT® Code 80350 refers to a laboratory test specifically designed to measure synthetic cannabinoids in biological samples such as urine, saliva, or blood. Synthetic cannabinoids are man-made chemicals that mimic the effects of THC, the active component in marijuana. Commonly known as 'spice' or 'K2,' these substances are often marketed under various names, including 'herbal incense' and 'legal marijuana.' Unlike natural cannabis, synthetic cannabinoids can produce a range of psychoactive effects, including anxiety, agitation, and hallucinations, which may be more pronounced than those associated with THC. These designer drugs are categorized into three main classes: classical cannabinoids (such as HU-210), cyclohexylphenols, and aminoalkylindoles. One of the significant challenges with synthetic cannabinoids is their rapidly evolving chemical structures, which are modified to evade detection in standard drug tests. It is important to note that synthetic cannabinoids will not be identified in immunoassay tests that are typically used for THC detection. The collection of samples for testing involves specific methods: blood samples are obtained through venipuncture, urine samples can be collected via random void or catheterization, and saliva samples are gathered using a swab or in a sample cup. The testing methodologies employed include liquid chromatography-tandem mass spectrometry for blood and saliva, while urine samples are initially screened using enzyme-linked immunosorbent assay and confirmed with high-performance liquid chromatography-tandem mass spectrometry. The use of code 80350 is appropriate when testing for 1-3 synthetic cannabinoids, whereas codes 80351 and 80352 are designated for testing 4-6 and 7 or more synthetic cannabinoids, respectively.

1. Indications

The laboratory test represented by CPT® Code 80350 is indicated for the detection and measurement of synthetic cannabinoids in patients who may be using these substances. The following conditions or situations may warrant the use of this test:

Substance Use Evaluation Patients suspected of using synthetic cannabinoids for recreational purposes or as an alternative to natural cannabis.
Clinical Assessment Individuals presenting with symptoms of intoxication or adverse reactions potentially related to synthetic cannabinoid use, such as anxiety, agitation, or hallucinations.
Monitoring Ongoing monitoring of patients with a history of synthetic cannabinoid use to assess for continued use or relapse.

2. Procedure

The procedure for testing synthetic cannabinoids involves several key steps, each critical for ensuring accurate results:

Sample Collection The first step in the procedure is the collection of biological samples. Blood samples are obtained through a process known as venipuncture, where a needle is inserted into a vein to draw blood. Urine samples can be collected either through random voiding or catheterization, depending on the clinical scenario and patient condition. Saliva samples are collected using a swab or in a sample cup, providing an alternative method for testing.
Initial Screening Once the samples are collected, the next step is the initial screening of urine samples using an enzyme-linked immunosorbent assay (ELISA). This method allows for the preliminary detection of synthetic cannabinoids in the urine, which is a common specimen type for drug testing.
Confirmation Testing If the initial screening indicates the presence of synthetic cannabinoids, confirmation testing is performed. For urine samples, high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) is utilized to confirm the presence and quantify the specific synthetic cannabinoids detected. Blood and saliva samples are also analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), which provides a highly sensitive and specific method for detecting these substances.

3. Post-Procedure

After the completion of the testing procedure, the results are analyzed and interpreted by qualified laboratory personnel. The findings will be reported to the requesting healthcare provider, who will then discuss the results with the patient. Depending on the outcomes, further clinical evaluation or intervention may be necessary. It is essential for healthcare providers to consider the potential implications of synthetic cannabinoid use on patient health and to provide appropriate counseling or referrals as needed. Additionally, follow-up testing may be recommended for ongoing monitoring of patients with a history of synthetic cannabinoid use.

Short Descr	CANNABINOIDS SYNTHETIC 1-3
Medium Descr	DRUG SCREENING CANNABINOIDS SYNTHETIC 1-3
Long Descr	Cannabinoids, synthetic; 1-3
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1